Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01769183
Other study ID # Ohr-003
Secondary ID
Status Completed
Phase Phase 2
First received January 14, 2013
Last updated February 9, 2015
Start date February 2013
Est. completion date August 2014

Study information

Verified date February 2015
Source Elman Retina Group
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy in the use of topical Squalamine Lactate Ophthalmic Solution, 0.2% in the treatment of retinal neovascularization resulting from proliferative diabetic retinopathy.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date August 2014
Est. primary completion date August 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age >= 18 years

- Individuals <18 years old are not being included because PDR is so rare in this age group that the diagnosis of PDR may be questionable.

- Diagnosis of diabetes mellitus (type 1 or type 2)

- Any one of the following will be considered to be sufficient evidence that diabetes is present:

- Current regular use of insulin for the treatment of diabetes

- Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes

- Documented diabetes by ADA and/or WHO criteria (see Procedures Manual for definitions)

- At least one eye meets the study eye criteria

- Able and willing provide informed consent

Exclusion Criteria:

- Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.

- A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).

- Individuals in poor glycemic control who, within the last 4 months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next 4 months should not be enrolled.

- Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied.

- Note: study participants cannot receive another investigational drug while participating in the study.

- Known allergy to any component of the study drug.

- Blood pressure > 180/110 (systolic above 180 or diastolic above 110).

- If blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible.

- Myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months prior to randomization.

- Systemic anti-VEGF or pro-VEGF treatment within 4 months prior to randomization.

- These drugs should not be used during the study.

- For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 3 years.

- Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment is used to determine when a pregnancy test is needed.

- Individual is expecting to move out of the area of the clinical center during the study.

- History of allergy to Squalamine

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Squalamine Lactate ophthalmic solution 0.2%
Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.

Locations

Country Name City State
United States Elman Retina Group, P.A. Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
Elman Retina Group

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Proportion with partial regression of neovascularization on fundus photography 1 month Yes
Primary Proportion with complete regression of neovascularization on fundus photography at one month 1 Month Yes
Secondary Mean Change in Visual Acuity from Baseline to 5 Months 5 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05650047 - Home OCT Guided Management Study of Subjects Diagnosed With Neovascular-AMD
Recruiting NCT05130385 - High Resolution Optical Coherence Tomography
Recruiting NCT03211741 - Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema Phase 4
Recruiting NCT02486484 - Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection Phase 2
Terminated NCT02088151 - Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina N/A
Completed NCT00564148 - Intravitreal Avastin in Proliferative Retinopathies Phase 2
Completed NCT02876198 - Study of the Modification of the Retinal Nerve Fiber Layer in Patients Treated With Intravitreous Injection of Anti-VEGF
Completed NCT01024998 - Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD) Phase 1
Completed NCT01102946 - Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy Phase 2
Completed NCT04650672 - Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.
Completed NCT01494805 - Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT00000153 - Krypton-Argon Regression of Neovascularization Study (KARNS) Phase 3